326 related articles for article (PubMed ID: 25138588)
1. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
[TBL] [Abstract][Full Text] [Related]
2. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Dmitrieva EA; Nikitin EA; Ignatova AA; Vorobyev VI; Poletaev AV; Seregina EA; Voronin KA; Polokhov DM; Maschan AA; Novichkova GA; Panteleev MA; Ptushkin VV
J Thromb Haemost; 2020 Oct; 18(10):2672-2684. PubMed ID: 32511880
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
4. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
8. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
[No Abstract] [Full Text] [Related]
9. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Thorp BC; Badoux X
Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Tobinai K; Uchida T; Fukuhara N; Nishikawa T
Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
[No Abstract] [Full Text] [Related]
16. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
[TBL] [Abstract][Full Text] [Related]
18. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
Aguilar C
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
[TBL] [Abstract][Full Text] [Related]
20. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Ruella M; Soubeyran P
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
